Published in Antimicrob Agents Chemother on November 01, 2002
Citrobacter infections in a general hospital: characteristics and outcomes. Eur J Clin Microbiol Infect Dis (2008) 1.61
Citrobacter spp. simultaneously harboring blaCTX-M, blaTEM, blaSHV, blaampC, and insertion sequences IS26 and orf513: an evolutionary phenomenon of recent concern for antibiotic resistance. J Clin Microbiol (2010) 1.09
Novel spectinomycin/streptomycin resistance gene, aadA14, from Pasteurella multocida. Antimicrob Agents Chemother (2005) 0.89
Citrobacter peritoneal dialysis peritonitis: rare occurrence with poor outcomes. Int J Med Sci (2013) 0.87
Complete Genome Sequence of Citrobacter freundii Myophage Moogle. Genome Announc (2015) 0.87
Biosynthesis and characterization of silver nanoparticles using panchakavya, an Indian traditional farming formulating agent. Int J Nanomedicine (2014) 0.85
Structural basis for the broad specificity of a new family of amino-acid racemases. Acta Crystallogr D Biol Crystallogr (2013) 0.84
Community-Acquired Pneumonia and Empyema Caused by Citrobacter koseri in an Immunocompetent Patient. Case Rep Pulmonol (2015) 0.81
Phenotypic detection and molecular characterization of beta-lactamase genes among Citrobacter species in a tertiary care hospital. Avicenna J Med (2016) 0.75
Finished Genome Sequence of the Highly Multidrug-Resistant Human Urine Isolate Citrobacter freundii Strain SL151. Genome Announc (2016) 0.75
The clonal relationship among the Citrobacter freundii isolated from the main hospital in Kermanshah, west of Iran. Iran J Microbiol (2016) 0.75
Citrobacter freundii induced endocarditis in a yearling colt. Can Vet J (2016) 0.75
Antimicrobial Resistance and Cytotoxicity of Citrobacter spp. in Maanshan Anhui Province, China. Front Microbiol (2017) 0.75
Assessment of chlorine tolerance profile of Citrobacter species recovered from wastewater treatment plants in Eastern Cape, South Africa. Environ Monit Assess (2017) 0.75
A rapid method for the identification of plasmid desoxyribonucleic acid in bacteria. Plasmid (1978) 26.51
The use of analytical isoelectric focusing for detection and identification of beta-lactamases. J Gen Microbiol (1975) 19.91
A rapid alkaline extraction method for the isolation of plasmid DNA. Methods Enzymol (1983) 9.81
Persistence of sulphonamide resistance in Escherichia coli in the UK despite national prescribing restriction. Lancet (2001) 6.37
Rapid pulsed-field gel electrophoresis protocol for typing of Escherichia coli O157:H7 and other gram-negative organisms in 1 day. J Clin Microbiol (1997) 5.62
Characterization of beta-lactamases in situ on polyacrylamide gels. Antimicrob Agents Chemother (1986) 4.73
Development of "oligotyping" for characterization and molecular epidemiology of TEM beta-lactamases in members of the family Enterobacteriaceae. Antimicrob Agents Chemother (1990) 4.45
Cefotaxime-resistant Enterobacteriaceae isolates from a hospital in Warsaw, Poland: identification of a new CTX-M-3 cefotaxime-hydrolyzing beta-lactamase that is closely related to the CTX-M-1/MEN-1 enzyme. Antimicrob Agents Chemother (1998) 4.24
Plasmid-mediated resistance to third-generation cephalosporins caused by point mutations in TEM-type penicillinase genes. Rev Infect Dis (1988) 3.49
Integrons and gene cassettes in the enterobacteriaceae. Antimicrob Agents Chemother (2001) 3.45
Class I integrons in Gram-negative isolates from different European hospitals and association with decreased susceptibility to multiple antibiotic compounds. J Antimicrob Chemother (1998) 3.21
Plasmid-mediated beta-lactamase (TEM-7) involved in resistance to ceftazidime and aztreonam. Rev Infect Dis (1988) 3.12
Concomitant dissemination of three extended-spectrum beta-lactamases among different Enterobacteriaceae isolated in a French hospital. J Antimicrob Chemother (1991) 3.08
Detection of beta-lactamase-mediated resistance. J Antimicrob Chemother (2001) 2.77
Outbreak of TEM-24-producing Enterobacter aerogenes in an intensive care unit and dissemination of the extended-spectrum beta-lactamase to other members of the family enterobacteriaceae. J Clin Microbiol (1996) 2.52
Achieving 100% typeability of Pseudomonas aeruginosa by pulsed-field gel electrophoresis. J Clin Microbiol (2000) 2.41
Concurrent outbreaks of extended-spectrum beta-lactamase-producing organisms of the family Enterobacteriaceae in a Warsaw hospital. J Antimicrob Chemother (1999) 2.26
Molecular characterization of integrons in Acinetobacter baumannii: description of a hybrid class 2 integron. Antimicrob Agents Chemother (2000) 2.25
Occurrence and detection of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and you may find. J Clin Microbiol (1997) 2.15
Detection and clinical significance of extended-spectrum beta-lactamases in a tertiary-care medical center. J Clin Microbiol (1997) 1.98
Molecular epidemiology of TEM-3 (CTX-1) beta-lactamase. Antimicrob Agents Chemother (1990) 1.73
Evolution, incidence, and susceptibility of bacterial bloodstream isolates from 519 bone marrow transplant patients. Clin Infect Dis (2001) 1.57
Bacteremias due to Citrobacter diversus and Citrobacter freundii. Incidence, risk factors, and clinical outcome. Arch Intern Med (1985) 1.48
Is surveillance for multidrug-resistant enterobacteriaceae an effective infection control strategy in the absence of an outbreak? J Infect Dis (2002) 1.37
Sequences of the genes for the TEM-20, TEM-21, TEM-22, and TEM-29 extended-spectrum beta-lactamases. Antimicrob Agents Chemother (1999) 1.34
Increased prevalence of class I integrons in Escherichia coli, Klebsiella species, and Enterobacter species isolates over a 7-year period in a German university hospital. J Clin Microbiol (2001) 1.23
Comparison of antimicrobial susceptibility of Citrobacter freundii isolates in two different time periods. J Microbiol Immunol Infect (2000) 1.14
Citrobacter diversus brain abscess and meningitis in neonates. JAMA (1981) 1.14
Bacteremia due to Citrobacter species: significance of primary intraabdominal infection. Clin Infect Dis (1996) 1.13
Citrobacter meningitis and brain abscess in infancy: epidemiology, pathogenesis, and treatment. J Pediatr (1988) 1.11
The molecular and clinical epidemiology of enterobacteriaceae-producing extended-spectrum beta-lactamase in a tertiary care hospital. J Infect (1998) 1.11
Molecular epidemiology of a nosocomial outbreak due to SHV-4-producing strains of Citrobacter diversus. J Clin Microbiol (1997) 1.06
Citrobacter diversus endocarditis. Am J Med Sci (2000) 0.98
National survey of the in vitro spectrum of piperacillin-tazobactam tested against more than 40,000 aerobic clinical isolates from 236 medical centers. Diagn Microbiol Infect Dis (1995) 0.92
Novel, plasmid-encoded, TEM-derived extended-spectrum beta-lactamase in Klebsiella pneumoniae conferring higher resistance to aztreonam than to extended-spectrum cephalosporins. Antimicrob Agents Chemother (1993) 0.92
In vitro efficacy of six cephalosporins tested against Enterobacteriaceae isolated at 38 North American medical centres participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. Int J Antimicrob Agents (2000) 0.89
Gram-negative bacillary meningitis in adult post-neurosurgical patients. Surg Neurol (1999) 0.87
[Bacteremic pneumonia caused by Citrobacter diversus: report of a case]. Rev Med Chil (1991) 0.81
[Community-acquired bacteremic pneumonia due to Citrobacter diversus]. An Med Interna (2000) 0.81
[A case of severe pneumonia in an elderly man, caused by Citrobacter freundii suspected to have a low susceptibility to imipenem/cilastatin sodium]. Nihon Kyobu Shikkan Gakkai Zasshi (1994) 0.77
The impact of conversion from prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant (2011) 3.42
Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant (2007) 3.02
Genetics of O-antigen biosynthesis in Pseudomonas aeruginosa. Microbiol Mol Biol Rev (1999) 2.73
Effects of the intensity of immunosuppressive therapy on outcome of treatment for CMV disease in organ transplant recipients. Am J Transplant (2010) 2.66
Immunologic and nonimmunologic factors: different risks for cadaver and living donor transplantation. Transplantation (2000) 2.25
Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients. Am J Transplant (2009) 2.25
American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation. Am J Transplant (2006) 2.11
Lessons learned from more than 1,000 pancreas transplants at a single institution. Ann Surg (2001) 1.89
Long-term follow-up of living kidney donors: quality of life after donation. Transplantation (1999) 1.65
Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant (2013) 1.58
Functional analysis of genes responsible for the synthesis of the B-band O antigen of Pseudomonas aeruginosa serotype O6 lipopolysaccharide. Microbiology (1999) 1.57
Sirolimus conversion regimen versus continued calcineurin inhibitors in liver allograft recipients: a randomized trial. Am J Transplant (2012) 1.55
Three rhamnosyltransferases responsible for assembly of the A-band D-rhamnan polysaccharide in Pseudomonas aeruginosa: a fourth transferase, WbpL, is required for the initiation of both A-band and B-band lipopolysaccharide synthesis. Mol Microbiol (1998) 1.54
"Plasma cell hepatitis" in liver allografts: identification and characterization of an IgG4-rich cohort. Am J Transplant (2013) 1.52
Cytomegalovirus in solid organ transplantation. Am J Transplant (2013) 1.48
Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant (2007) 1.47
Fatal Falciparum malaria in Canadian travellers. Can Commun Dis Rep (1996) 1.46
Selective retransplant after graft loss to nonadherence: success with a second chance. Am J Transplant (2009) 1.44
Guidance on novel influenza A/H1N1 in solid organ transplant recipients. Am J Transplant (2009) 1.42
2,500 living donor kidney transplants: a single-center experience. Ann Surg (2001) 1.41
Involvement of the rml locus in core oligosaccharide and O polysaccharide assembly in Pseudomonas aeruginosa. Microbiology (2000) 1.30
PilM/N/O/P proteins form an inner membrane complex that affects the stability of the Pseudomonas aeruginosa type IV pilus secretin. J Mol Biol (2009) 1.26
Lipopolysaccharide core phosphates are required for viability and intrinsic drug resistance in Pseudomonas aeruginosa. Mol Microbiol (2000) 1.24
Regulatory dendritic cell infusion prolongs kidney allograft survival in nonhuman primates. Am J Transplant (2013) 1.22
Three-component-mediated serotype conversion in Pseudomonas aeruginosa by bacteriophage D3. Mol Microbiol (2001) 1.22
Immunolocalisation of Burkholderia cepacia in the lungs of cystic fibrosis patients. J Med Microbiol (2001) 1.19
Periplasmic domains of Pseudomonas aeruginosa PilN and PilO form a stable heterodimeric complex. J Mol Biol (2009) 1.14
Clinical impact of ganciclovir-resistant cytomegalovirus infections in solid organ transplant patients. Transpl Infect Dis (2006) 1.09
Latent tuberculosis infection: is universal screening the right approach? Am J Transplant (2014) 1.08
Diagnosis and management of tuberculosis in transplant donors: a donor-derived infections consensus conference report. Am J Transplant (2012) 1.08
Molecular mechanisms of cefoxitin resistance in Escherichia coli from the Toronto area hospitals. Diagn Microbiol Infect Dis (2001) 1.03
Pulmonary thromboembolism during adult liver transplantation: incidence, clinical presentation, outcome, risk factors, and diagnostic predictors. Br J Anaesth (2011) 1.02
Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant (2009) 1.02
2202 kidney transplant recipients with 10 years of graft function: what happens next? Am J Transplant (2008) 1.02
Characterization of the PilN, PilO and PilP type IVa pilus subcomplex. Mol Microbiol (2011) 1.01
Invasive pneumococcal disease in adult hematopoietic stem cell transplant recipients: a decade of prospective population-based surveillance. Bone Marrow Transplant (2008) 1.00
Preventive intervention for living donor psychosocial outcomes: feasibility and efficacy in a randomized controlled trial. Am J Transplant (2013) 0.96
Immunogenicity of pneumococcal vaccine in renal transplant recipients--three year follow-up of a randomized trial. Am J Transplant (2007) 0.96
Rapid discontinuation of steroids in living donor kidney transplantation: a pilot study. Am J Transplant (2001) 0.94
Acid-stress-induced changes in enterohaemorrhagic Escherichia coli O157 : H7 virulence. Microbiology (2009) 0.94
Vancomycin-resistant enterococci on a renal ward in an Ontario hospital. Can Commun Dis Rep (1996) 0.93
Comparison of quantiferon-TB gold with tuberculin skin test for detecting latent tuberculosis infection prior to liver transplantation. Am J Transplant (2007) 0.93
Differentiation and quantitation of human herpesviruses 6A, 6B and 7 by real-time PCR. J Virol Methods (2003) 0.92
Fungal infections in transplant recipients receiving alemtuzumab. Transplant Proc (2005) 0.90
Pulmonary zygomycosis in solid organ transplant recipients in the current era. Am J Transplant (2009) 0.89
Delay of adequate empiric antibiotic therapy is associated with increased mortality among solid-organ transplant patients. Am J Transplant (2009) 0.89
Predictors of virological response in HIV-infected patients to salvage antiretroviral therapy that includes nelfinavir. Antivir Ther (2001) 0.89
Invasive pneumococcal disease in solid organ transplant recipients--10-year prospective population surveillance. Am J Transplant (2007) 0.88
Decreased acute rejection in kidney transplant recipients is associated with decreased chronic rejection. Ann Surg (1999) 0.88
A national survey of independent living donor advocates: the need for practice guidelines. Am J Transplant (2012) 0.88
Re-examination of the lymphocytotoxic crossmatch in liver transplantation: can C4d stains help in monitoring? Am J Transplant (2011) 0.88
Recommended curriculum for subspecialty training in transplant infectious disease on behalf of the American Society of Transplantation Infectious Diseases Community of Practice Educational Initiatives Working Group. Transpl Infect Dis (2010) 0.87
Treprostinil, a prostacyclin analog, ameliorates ischemia-reperfusion injury in rat orthotopic liver transplantation. Am J Transplant (2011) 0.86
Pre-emptive transplants for patients with renal failure: an argument against waiting until dialysis. Transplantation (2000) 0.86
Late cytomegalovirus transmission and impact of T-depletion in clinical islet transplantation. Am J Transplant (2011) 0.85
Alginate as an auxiliary bacterial membrane: binding of membrane-active peptides by polysaccharides. J Pept Res (2005) 0.84
Effect of early cyclosporine levels on kidney allograft rejection. Clin Transplant (1997) 0.83
Bacteremia in lung transplant recipients in the current era. Am J Transplant (2006) 0.83
Donor-derived bacteremia in liver transplant recipients despite antibiotic prophylaxis. Am J Transplant (2013) 0.83
Targeted versus universal antifungal prophylaxis among liver transplant recipients. Am J Transplant (2014) 0.83
A prospective, randomized, open-label study of steroid withdrawal in pancreas transplantation-a preliminary report with 6-month follow-up. Transplant Proc (2001) 0.82
Randomized controlled trial of high-dose intradermal versus standard-dose intramuscular influenza vaccine in organ transplant recipients. Am J Transplant (2013) 0.82
Mycobacterial infections after kidney transplant. Transplant Proc (2005) 0.82
Pneumocystis jirovecii pneumonia after rituximab therapy for antibody-mediated rejection in a renal transplant recipient. Transpl Infect Dis (2008) 0.81
Analysis and clinical correlation of genetic variation in cytomegalovirus. Transpl Infect Dis (2011) 0.81
1.7 year follow-up after bortezomib therapy for refractory antibody mediated rejection. Clin Transpl (2010) 0.81
Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients. Am J Transplant (2013) 0.81
Successful lung transplant in a child with cystic fibrosis and persistent Blastobotrys rhaffinosifermentans infection. Pediatr Transplant (2014) 0.81
Lamivudine for hepatitis B in liver transplantation: a single-center experience. Transplantation (2000) 0.80
Kidney transplant using pediatric donors--effect on long-term graft and patient survival. Transplant Proc (2000) 0.80
Liver transplantation outcome in patients with angiographically proven coronary artery disease: a multi-institutional study. Am J Transplant (2012) 0.80
Multicenter survey of daclizumab induction in simultaneous kidney-pancreas transplant recipients. Transplantation (2001) 0.80
Posterior reversible encephalopathy syndrome in liver transplant patients: clinical presentation, risk factors and initial management. Am J Transplant (2012) 0.80
Outcome of other organs recovered during in situ split-liver procurements. Liver Transpl (2001) 0.80
Pretransplant immunosuppression for pancreas transplants alone in nonuremic diabetic recipients. Transplant Proc (2001) 0.80
Vascular graft thrombosis after pancreas transplantation: comparison of the FK 506 and cyclosporine eras. Transplant Proc (1999) 0.79
Genetic and biochemical characterization of an operon involved in the biosynthesis of 3-deoxy-D-manno-octulosonic acid in Pseudomonas aeruginosa. FEMS Microbiol Lett (1999) 0.79
A comparative study of the use of selective digestive decontamination prophylaxis in living-donor liver transplant recipients. Transpl Infect Dis (2014) 0.79
Living liver donor surgery: report of initial anesthesia experience. J Clin Anesth (2000) 0.79
A comparison of multifaceted versus Clostridium difficile-focused VRE surveillance strategies in a low-prevalence setting. Infect Control Hosp Epidemiol (2001) 0.79
A novel antimicrobial peptide significantly enhances acid-induced killing of Shiga toxin-producing Escherichia coli O157 and non-O157 serotypes. Microbiology (2011) 0.78
Kidney and pancreas transplantation without a crossmatch in select circumstances--it can be done. Clin Transplant (2001) 0.78
5,000 kidney transplants--a single-center experience. Clin Transpl (2000) 0.78
Donor-derived infection: old problem, new solutions? Am J Transplant (2008) 0.78
Beta-cell replacement therapy (pancreas and islet transplantation) for treatment of diabetes mellitus: an integrated approach. Transplant Proc (2004) 0.78
Discipline of Transplant Infectious Diseases (ID). Foreword. Am J Transplant (2009) 0.78
Natural history of recurrent hepatitis C after liver transplantation. Transplant Proc (2001) 0.77
Anti-CD25 antibody (daclizumab) maintenance therapy in pancreas transplantation. Transplant Proc (2010) 0.77
Mycophenolate mofetil in pancreas transplantation. Transplantation (1998) 0.77
Non-nucleoside reverse transcriptase inhibitor failure impairs HIV-RNA responses to efavirenz-containing salvage antiretroviral therapy. AIDS (2001) 0.77
Successful liver transplantation in a patient with severe haemophilia A and a high-titre factor VIII inhibitor. Haemophilia (2004) 0.77
Severe Legionnaire's disease caused by Legionella longbeachae in a long-term renal transplant patient: the importance of safe living strategies after transplantation. Transpl Infect Dis (2012) 0.77
Computed tomographic and cytologic assessment of cystic pancreatic neoplasms: a difficult preoperative diagnosis. Can Assoc Radiol J (1993) 0.77
Donor-specific alloantibody upregulation after influenza vaccination in transplant recipients. Am J Transplant (2011) 0.77
Secreted Wnt antagonists during eradication of cytomegalovirus infection in solid organ transplant recipients. Am J Transplant (2013) 0.77
Response to questions regarding the design and results of the IMPACT trial. Am J Transplant (2011) 0.77
A multicenter evaluation of pandemic influenza A/H1N1 in hematopoietic stem cell transplant recipients. Transpl Infect Dis (2013) 0.76
Should I accept this kidney? Clin Transplant (2000) 0.76
Epstein-Barr virus serology and posttransplant lymphoproliferative disease in lung transplantation. Transplantation (2001) 0.76
Pancreas after kidney transplants in posturemic patients with type I diabetes mellitus. J Am Soc Nephrol (2001) 0.76